08:00 , Nov 25, 2013 |  BioCentury  |  Emerging Company Profile

Armo: Reviving IL-10

Armo Biosciences Inc. is set to emerge from stealth mode this week with a $20 million series A round and a license to a pegylated IL-10 program that was tested by Schering-Plough Corp. for autoimmune...
08:00 , Nov 5, 2012 |  BioCentury  |  Finance

Skyline's limit

Skyline's limit Skyline Ventures isn't talking about its decision to suspend fundraising for a sixth fund, but its performance compared to other healthcare VCs shows just how hard it is to raise money these days....
07:00 , May 5, 2008 |  BioCentury  |  Strategy

Buying biology

Buying biology Completed Acquired company Acquirer Value Biology focus 2006 Sirna Merck (NYSE:MRK) $1,100 RNAi 2008 Sirtris (NASDAQ:SIRT) GlaxoSmithKline (LSE:GSK; NYSE:GSK) $720 Sirtuins 2007 Adnexus Bristol-Myers (NYSE:BMY) $505 Protein engineering 2007 Domantis GlaxoSmithKline (LSE:GSK; NYSE:GSK)...
08:00 , Nov 19, 2007 |  BioCentury  |  Finance

Ebb & Flow

Skyline Ventures capitalized on a string of acquisitions of portfolio companies and IPO exits over the last few years by raising a fifth fund of $350 million in only four months, almost doubling its funds...
07:00 , Aug 6, 2007 |  BC Week In Review  |  Company News

OxiGene management update

OxiGene Inc. (OXGN; SSE:OXGN), Waltham, Mass.   Business: Cancer, Ophthalmic   Hired: Patricia Walicke as CMO and VP, formerly VP of clinical and regulatory affairs at Amgen Inc. 's Avidia Inc. subsidiary  ...
07:00 , Jun 18, 2007 |  BC Week In Review  |  Company News

Anacor management update

Anacor Pharmaceuticals Inc. , Palo Alto, Calif.   Business: Infectious   Hired: Paulette Dillon as CBO, formerly SVP and CBO of Avidia Inc.  ...
07:00 , Apr 30, 2007 |  BioCentury  |  Strategy

MedImmune chronicles

MedImmune chronicles Since late 2000, MedImmune's stock performance has lagged its peers, as gauged by a price-weighted index consisting of Amgen (AMGN), Biogen Idec (BIIB), Genentech (DNA), Genzyme (GENZ) and Gilead (GILD). In fact, prior...
07:00 , Mar 26, 2007 |  BioCentury  |  Finance

Morgenthaler exits

Morgenthaler exits Company Stage at investment Time held Exit Valuation Avidia Early 2 years Acquired by Amgen in 2006 $290 Morphotek Mid 3 years Proposed acquisition by Eisai last week $350 Orexigen Early 2 years...
08:00 , Jan 1, 2007 |  BioCentury  |  Finance

2007 Financial Markets Preview: M&A upside

Last year was a banner year for financing in the biotech sector. A total of $29.6 billion was raised worldwide, including $23.9 billion in the public space. But that doesn't mean investors will be fatigued...
08:00 , Nov 13, 2006 |  BioCentury  |  Strategy

Genentech departs from script

Genentech Inc. last week made the first acquisition in its 30-year history, but the company made clear that its decision to buy partner Tanox Inc. was based on an expectation of future growth of asthma...